Antimyotonic effects of tocainide enantiomers on skeletal muscle fibers of congenitally myotonic goats

被引:8
作者
Camerino, DC
Pierno, S
De Luca, A
Bryant, SH
机构
[1] Univ Bari, Fac Farm, Dipartimento Farmacobiol, Unita Farmacol, I-70125 Bari, Italy
[2] Univ Cincinnati, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA
关键词
myotonia; antiarrhythmic drugs; skeletal muscle; chloride channels; excitability;
D O I
10.1016/S0960-8966(99)00101-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Tocainide is effective in the symptomatic treatment of myotonic syndromes for its ability to reduce the high Frequency discharges of action potentials typical of the disease, by blocking voltage-gated sodium channels. However, its use is restricted by serious side effects. In spite of its chiral structure, tocainide is clinically used as a racemic mixture. Since the optical isomers may differ in their efficacy and toxicity, the present study was aimed at evaluating the antimyotonic activity of the pure R(-) and S(+) enantiomers of tocainide, on the abnormal membrane hyperexcitability of external intercostal muscle fibers of congenitally myotonic goats. The excitability parameters were recorded in vitro by means of the standard two-microelectrode current-clamp technique before and after the addition of the compounds. The R(-) enantiomer of tocainide at concentrations as low as 10 mu M potently counteracted the abnormal excitability of myotonic fibers, by increasing the threshold current, and decreasing the latency of the action potential and firing capability. Also, this concentration of R-(-) tocainide almost completely abolished the abnormal spontaneous electrical activity occurring in about 70-80% of the myotonic fiber. The S(+) enantiomer was remarkably Less potent since up to 100 mu M did not restore the normal excitability pattern. The results show that most of the antimyotonic activity of tocainide resides in the R(-) enantiomer suggesting that its clinical use may allow a significant reduction of the doses and possibly of the side effects. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:160 / 164
页数:5
相关论文
共 34 条
[11]   Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide [J].
De Luca, A ;
Natuzzi, F ;
Falcone, G ;
Duranti, A ;
Lentini, G ;
Franchini, C ;
Tortorella, V ;
Camerino, DC .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (06) :777-787
[12]  
DELUCA A, 1992, J PHARMACOL EXP THER, V260, P364
[13]  
DELUCA A, 1991, N-S ARCH PHARMACOL, V344, P596
[14]  
DeLuca A, 1997, J PHARMACOL EXP THER, V282, P93
[15]   STEREOSELECTIVITY IN CENTRAL ANALGESIC ACTION OF TOCAINIDE AND ITS ANALOGS [J].
FRANCHINI, C ;
NOJA, FC ;
CORBO, F ;
LENTINI, G ;
TORTORELLA, V ;
BARTOLINI, A ;
GHELARDINI, C ;
MATUCCI, R ;
GIOTTI, A .
CHIRALITY, 1993, 5 (03) :135-142
[16]   ALTERED NA+ CHANNEL ACTIVITY AND REDUCED CL- CONDUCTANCE CAUSE HYPEREXCITABILITY IN RECESSIVE GENERALIZED MYOTONIA (BECKER) [J].
FRANKE, C ;
IAIZZO, PA ;
HATT, H ;
SPITTELMEISTER, W ;
RICKER, K ;
LEHMANNHORN, F .
MUSCLE & NERVE, 1991, 14 (08) :762-770
[17]   MOLECULAR-BASIS OF THOMSEN DISEASE (AUTOSOMAL DOMINANT MYOTONIA-CONGENITA) [J].
GEORGE, AL ;
CRACKOWER, MA ;
ABDALLA, JA ;
HUDSON, AJ ;
EBERS, GC .
NATURE GENETICS, 1993, 3 (04) :305-310
[18]  
GREEN JR, 1978, STAT TREATMENT EXPT, P86
[19]  
Iaizzo P A, 1991, Neuromuscul Disord, V1, P47, DOI 10.1016/0960-8966(91)90042-Q
[20]   TREATMENT OF MYOTONIA WITH ANTIARRHYTHMIC DRUGS [J].
KWIECINSKI, H ;
RYNIEWICZ, B ;
OSTRZYCKI, A .
ACTA NEUROLOGICA SCANDINAVICA, 1992, 86 (04) :371-375